Long-term effects of B-type natriuretic peptide infusion after acute myocardial infarction in a rat model

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 1, 2010, Pages 14-20

  George, Isaac ^a   Xydas, Steve ^a   Klotz, Stefan ^a   Hay, Ilan ^a   Ng, Chuck ^a   Chang, Jonathan ^a   Xu, Kai ^a   Li, Zhihe ^b   Protter, Andrew A ^b   Wu, Ed X ^c   Oz, Mehmet C ^a   Wang, Jie ^a,d  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b SCIOS INC   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

Myocardial infarction; Natriuretic peptides; Remodeling

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; ECHOGRAPHY; EX VIVO STUDY; HEART FUNCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEMODYNAMICS; HISTOLOGY; HYPOTHESIS; IN VIVO STUDY; INFUSION PUMP; MALE; NONHUMAN; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; RAT; SHAM PROCEDURE;

ANIMALS; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; MYOCARDIAL INFARCTION; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 75749130708     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181c5e743     Document Type: Article

References (28)

1. Lincoln TM, Cornwell TL. Intracellular cyclic GMP receptor proteins. FASEB. 1993;7:328-338.
2. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Nat Acad Sci USA. 2000;97:4239-4244.
3. Lattion AL, Michel JB, Arnauld E, et al. Myocardial recruitment during ANF mRNA increase with volume overload in the rat. Am J Physiol. 1986; 251:H890-H896.
4. Saito Y, Nakao K, Arai H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA. 2000;97:4239-4244.
5. Kapoun AM, Liang F, O'Young G, et al. B-Type natriuretic peptide exerts broad functional opposition to transforming growth factor-b in primary human cardiac fibroblasts. Circ Res. 2004;94:453-461.
6. Troughton RW, Prior DL, Pereirra JJ, et al. Plasma B-type natriuretic peptide levels in systolic heart failure. J Am Coll Cardiol. 2004;43:416-422.
7. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246-253.
8. Fonarow GC. B-type natriuretic peptide: spectrum of application. Nesiritide (recombinant BNP) for heart failure. Heart Fail Rev. 2003;8: 321-325.
9. He J, Chen Y, Huang Y, et al. Effect of long-term B-type natriuretic peptide treatment on left ventricular remodeling and function after myocardial infarction in rats. Eur J Pharm. 2009;602:132-137.
10. Mentzer RM, Oz MC, Sladen RN, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery. J Am Coll Cardiol. 2007;49:716-726.
11. Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2001;37:1820-1826.
12. Xydas S, Kherani AR, Chang JS, et al. Beta(2)-adrenergic stimulation attenuates left ventricular remodeling, decreases apoptosis, and improves calcium homeostasis in a rodent model of ischemic cardiomyopathy. J Pharmacol Exp Ther. 2006;317:553-556.
13. He KL, Yi GH, Sherman W, et al. Autologous skeletal myoblast transplantation improved hemodynamics and left ventricular function in chronic heart failure dogs. J Heart Lung Transplant. 2005;24:1940-1949.
14. Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med. 2002;162:1689-1694.
15. Zijlstra F, Patel A, Jones M, et al. Clinical characteristics and outcomes of patients with early (,2h), intermediate (2-4h), and late (.4h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J. 2002;23:550-557.
16. Van der Zander K, Houben AJHM, Hofstra L, et al. Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study. Am J Physiol Heart Circ Physiol. 2003;285:H1206-H1212.
17. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84:1581-1588.
18. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184-3189.
19. Yasue H, Yoshimura M. Natriuretic peptides in the treatment of heart failure. J Card Fail. 1996;2:S277-S285.
20. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-328.
21. Chen HH, Grantham A, Schirger JA, et al. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol. 2000;36:1706-1712.
22. Ren B, Shen Y, Shao H, et al. Brain natriuretic peptide limits myocardial infarct size dependent of nitric oxide synthase in rats. Clin Chim Acta. 2007;377:83-87.
23. Michaels AD, Klein A, Madden JA, et al. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation. 2003;107:2697-2701.
24. Abraham WT, Adams KF, Fonarow GC, et al; ADHERE scientific advisory and investigators ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications. J Am Coll Cardiol. 2005;46:57-64.
25. Kohno M, Yokokawa K, Horio T, et al. Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Res. 1992;70:241-247.
26. D'Souza SP, Yellon DM, Martin C, et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol. 2003;284:H1592-H1600.
27. Yamamoto K, Burnett JC Jr, Redfield MM. Effect of the endogenous natriuretic peptide system on ventricular and coronary function in the failing canine heart. Am J Physiol. 1997;273:H2406-H2414.
28. Li Y, Kishimoto I, Saito Y, et al. Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation. 2002;106:1722-1728.